Neurizon Therapeutics Limited (NUZ.AX)
40 additional metrics available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUDm | 3 | 3 | 3 | 3 | 0 | 0 | 0 | N/A |
| Operating profit | AUDm | ||||||||
| Net profit | AUDm | -1 | -2 | -2 | -9 | -9 | -17 | -6 | N/A |
| EPS reported | AUD | ||||||||
| Operating cashflow per share | AUD | ||||||||
| Capex per share | AUD | ||||||||
| FCF per share | AUD | ||||||||
| Free cash flow | AUDm | ||||||||
| Net debt | AUDm | ||||||||
| Book value equity | AUDm | ||||||||
| Book value per share | AUD | ||||||||
| Number of shares | m | ||||||||
| DPS (TTM paid) | AUD |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | ||||||||
| P/B LTM | x | ||||||||
| P/S LTM | x | ||||||||
| P/FCF LTM | x | ||||||||
| EV/EBITDA LTM | x | ||||||||
| EV/Sales LTM | x | ||||||||
| Earnings Yield LTM | % | ||||||||
| FCF Yield | % | ||||||||
| Quality | |||||||||
| ROE | % | ||||||||
| ROIC | % | ||||||||
| Operating margin | % | ||||||||
| Gross margin | % | ||||||||
| FCF/Sales | % | ||||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | ||||||||
| Sales Growth YoY | % | ||||||||
| Net Income Growth YoY | % | ||||||||
| FCF Growth | % | ||||||||
| Operating Profit Growth | % | ||||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | ||||||||
| Dividend Growth | % | ||||||||
| Payout Ratio | % | ||||||||
| FCF/Debt | x | ||||||||
| Net Debt/EBITDA | x | ||||||||
| EBIT/Net interest | x | ||||||||
| Net debt/market cap | % | ||||||||
| Net debt/Equity | % | ||||||||
| Gross debt/equity | % | ||||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Neurizon Therapeutics Limited (NUZ.AX)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free